-
A blessing in disguise: What has my FSHD given me?
I’m reading “Eyes to the Wind: A Memoir of Love and Death, Hope and Resistance” by Ady Barkan, a late lawyer and political activist who had ALS. It’s been a tough read so far. In the book, Barkan recounts his experiences after being diagnosed with ALS in his early 30s. He does an excellent job…
-
5 things I didn’t anticipate about caring for teens with Duchenne MD
Life is lived in seasons, at least here in Nebraska, where we experience all four of them. Some days offer nearly perfect weather: The sun is shining, the temperature is in the mid-70s, and I can smell the thaw of winter and feel the hope of spring. Then there are the cloudy winter days when…
-
LGMD scientific workshop gathers experts to tackle unmet needs
Patients and experts in limb-girdle muscular dystrophy (LGMD), along with drug developers, community leaders, and regulatory agency personnel, came together for the LGMD Scientific Workshop to discuss how to tackle the unmeet therapeutic needs of people with these muscle-wasting diseases. The workshop, held in early February in Maryland, was hosted by The Speak Foundation, a…
-
15th Annual Champions to CureDuchenne Returns to The University of Texas Golf Club on April 6 to Find a Cure for Duchenne Muscular Dystrophy
“Disco For Duchenne” Gala Features Dancing, Drinks, a Culinary Experience and More to Help Advance Research for the Rare Disease AUSTIN, Texas., February 28, 2024 – CureDuchenne, a leading global nonprofit focused on finding and funding a cure for Duchenne muscular dystrophy, and the Revell family of Austin will host the 15th annual fundraiser gala, Champions…
-
CureDuchenne Webinar with Dyne Therapeutics | Advancing the Promise of FORCE to Deliver for Patients
Dyne Therapeutics will present initial clinical data, first released on January 3rd, 2024, from the DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping. Recorded Tuesday, February 13, 2024 Watch Recording The post CureDuchenne Webinar with Dyne Therapeutics | Advancing the Promise of FORCE to Deliver…
-
New cell-based study reveals autoimmune mechanism in DM2
A cell-based study revealed the biological mechanism behind the increased tendency for people with myotonic dystrophy type 2 (DM2) to develop autoimmune diseases. Researchers found that the genetic defect that causes DM2, called a repeat expansion, indirectly triggered an abnormal, antiviral immune response in patient cells. “That was our ‘aha’ moment,” study lead Claudia Günther,…
-
Breaking news: Rare Disease Day Congressional Hearing to Address the BENEFIT Act
On Thursday, February 29th, Rare Disease Day, the House Energy and Commerce Committee will hold a congressional hearing, titled “Legislative Proposals to Support Patients with Rare Diseases” at 10:00 am ET. This hearing will review 18 pieces of legislation intended to support patients living with rare diseases, including the Better Empowerment Now to Enhance and…
-
In choosing a college, my son with DMD is already winning
I am a competitive former college athlete married to a someone who is equally competitive and also was a college athlete. We like to win and try to position ourselves in ways to make it possible. However, when three of our sons, Max, 18, Rowen, 15, and Charlie, 13, were diagnosed with Duchenne muscular dystrophy…
-
Revised Community-Led Duchenne Guidance Published: Developing Potential Treatments for the Entire Spectrum of Disease
Today PPMD is pleased to share that the revised community-led Duchenne Guidance has been published in the Journal of Neuromuscular Diseases! This Community Draft Guidance was submitted to the FDA at the end of 2022. Serving as an update to the original guidance that was submitted in July 2014, the revision of this document is…
-
Exon-skipping AOC 1044 gets FDA rare pediatric disease status
The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to AOC 1044, an experimental therapy for people with Duchenne muscular dystrophy (DMD) caused by mutations that are amenable to exon 44 skipping. The FDA gives the designation to treatments with the potential to improve care for disorders that primarily affect children…
